



## Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

May 19, 2021

CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- [Cullinan Oncology, Inc.](#) (Nasdaq: CGEM) ("Cullinan"), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4<sup>th</sup>, 2021 at 10:30 am ET ("Pearl Clinical Update Webinar").

During the webinar, members of Cullinan's management team will review updated safety and efficacy data from an ongoing Phase 1/2a trial evaluating CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion mutations (Ins20).

As previously announced, data from this trial was selected for a poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will include information using an April 1<sup>st</sup>, 2021 data cutoff and it will be available for on-demand viewing starting on Friday, June 4<sup>th</sup> at 9:00 am ET. Cullinan is hosting the Pearl Clinical Update Webinar at 10:30 am ET, after the poster release, in order to align with ASCO's embargo policies.

### Pearl Clinical Update Webinar Information

Please register for the webinar directly [here](#), or through the 'Events' section on Cullinan's investor website [here](https://investors.cullinanoncology.com/news-events/events) (https://investors.cullinanoncology.com/news-events/events). All materials presented will be accessible on the Cullinan website, and an archived recording of the live audio webcast will be available on Cullinan's website for approximately 30 days.

### ASCO Poster Presentation Information

**Abstract Title:** Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20)

**Abstract Number:** 9077

**Date and Time:** June 4<sup>th</sup>, 2021, 9:00 am ET (On-Demand)

### About CLN-081

CLN-081 is an orally available, irreversible EGFR inhibitor that was designed to selectively target cells expressing mutant EGFR variants, including Ins20, while sparing cells expressing wild type EGFR. In preclinical studies, CLN-081 demonstrated inhibition against traditional sensitizing mutations (exon 19 deletions and L858R), Ins20 (the third most common EGFR mutation), and other less common mutations (G719X, L861Q, and S768I).

Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients with NSCLC harboring Ins20 mutations that have progressed post chemotherapy. Based on pre-specified efficacy and safety criteria, Cullinan recently initiated Phase 2a dose expansion in the 100 mg BID dosing cohort, which will enable enrollment of up to 36 patients at this dose level, inclusive of 13 previously enrolled patients.

### About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that strives to deliver results for our various stakeholders through disciplined capital allocation, decisive action, prudent risk taking and creative business development. We seek to drive shareholder returns by focusing on the patient. The Company's strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at [www.cullinanoncology.com](http://www.cullinanoncology.com).

### Forward-Looking Statements

This press release contains forward-looking statements of Cullinan Oncology, Inc. ("Cullinan," "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan's beliefs and expectations regarding our preclinical and clinical development plans, clinical trial designs, clinical and therapeutic potential, and strategy of our product candidates, including but not limited to our expectations and beliefs around the safety and activity of CLN-081. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our therapeutic candidates; risks related to the impact of COVID-19 affecting countries or regions in which we have operations or do business, including potential negative impacts on our employees, customers, supply chain and production as well as global economies and financial markets; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law,

neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

**Contacts:**

Investor Relations

[investors@cullinanoncology.com](mailto:investors@cullinanoncology.com)

Jeffrey Trigilio

+1 617.410.4650

[jtrigilio@cullinanoncology.com](mailto:jtrigilio@cullinanoncology.com)